Cladribine tablets, a novel intermittent immunosuppressant expected soon in North America, has been shown to be highly efficacious in reducing annualized relapse rates (ARR) and disability progression over a sustained period, according to the most recent data. Read More

Thursday Edition
Friday Edition

Head-to-head (to head) studies
Switching/sequencing studies
New analyses of DMT effectiveness
Use of gadolinium – consensus statement
Pregnancy rate on the increase in women with MS Read More

Thursday Edition
Saturday Edition

Teriflunomide
Dimethyl fumarate
Fingolimod
Cladribine
Alemtuzumab
Ocrelizumab

Read More

Friday Edition
Saturday Edition

Oral DMT use
Disease reactivation and miscarriage
French Canadians
Biomarkers
Concussion and MS Read More